NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 135.18

Change

-0.12 (-0.09)%

Market Cap

USD 81.07B

Volume

1.98M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.30B
BHVN Biohaven Pharmaceutical Holdin..

+0.03 (+0.08%)

USD 3.38B
RCUS Arcus Biosciences Inc

+0.42 (+2.47%)

USD 1.48B
NUVB Nuvation Bio Inc

-0.01 (-0.33%)

USD 0.70B
ANRO Alto Neuroscience, Inc.

-0.41 (-3.06%)

USD 0.35B
DNA Ginkgo Bioworks Holdings

+0.03 (+0.48%)

USD 0.34B
ADCT ADC Therapeutics SA

N/A

USD 0.28B
CYBN Cybin Inc

-0.01 (-2.90%)

USD 0.16B
ANVS Annovis Bio Inc

-0.11 (-1.28%)

USD 0.11B
MAIA MAIA Biotechnology Inc.

+0.12 (+3.83%)

USD 0.08B

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 20.43 % 0.00 %

+0.14 (+0.68%)

N/A
THNR Amplify ETF Trust 12.82 % 0.00 %

+0.18 (+0.68%)

N/A
TTTX:CA Global X Innovative Bluec.. 9.62 % 0.00 %

+0.34 (+0.68%)

CAD 3.10M
PJIO PGIM ETF Trust 7.59 % 0.00 %

+0.72 (+0.68%)

USD 0.01B
BELT BlackRock Long-Term U.S. .. 7.08 % 0.00 %

+0.20 (+0.68%)

N/A
AADR AdvisorShares Dorsey Wrig.. 6.40 % 0.00 %

+0.83 (+0.68%)

USD 0.02B
DXIF:CA Dynamic Active Internatio.. 6.23 % 0.00 %

N/A

CAD 4.70M
PJBF 5.55 % 0.00 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

N/A

N/A
LEAD-B:CA Evolve Future Leadership .. 5.06 % 0.00 %

N/A

CAD 0.02B
LRNZ TrueShares Technology AI .. 4.68 % 0.00 %

+0.29 (+0.68%)

USD 0.03B
PINK Simplify Exchange Traded .. 3.70 % 0.00 %

+0.18 (+0.68%)

USD 0.25B
HAZ:CA Global X Active Global Di.. 3.68 % 0.94 %

+0.41 (+0.68%)

CAD 0.44B
SPWO SP Funds Trust 3.48 % 0.00 %

+0.18 (+0.68%)

USD 0.01B
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

+0.20 (+0.68%)

N/A
IDVO Amplify International Enh.. 3.09 % 0.00 %

+0.28 (+0.68%)

USD 0.10B
PTIN Pacer Trendpilot Internat.. 2.48 % 0.00 %

+0.34 (+0.68%)

USD 0.14B
DSAE:CA Desjardins Sustainable Am.. 2.22 % 0.00 %

N/A

CAD 1.19M
APIE Trust For Professional Ma.. 1.81 % 0.00 %

+0.15 (+0.68%)

USD 0.28B
AVDE Avantis® International E.. 1.73 % 0.00 %

+0.70 (+0.68%)

USD 5.02B
AVSD American Century ETF Trus.. 1.61 % 0.00 %

+0.48 (+0.68%)

USD 0.14B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

+0.13 (+0.68%)

USD 0.77B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

+0.46 (+0.68%)

N/A
PPH VanEck Pharmaceutical ETF 0.00 % 0.36 %

+0.20 (+0.68%)

USD 0.72B
RFAP 0.00 % 0.83 %

N/A

N/A
FPXI First Trust International.. 0.00 % 0.70 %

+0.24 (+0.68%)

USD 0.14B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.02 (0.68%)

CAD 0.05B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

+0.54 (+0.68%)

USD 0.49B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

+0.65 (+0.68%)

USD 0.68B
LEAD-U:CA 0.00 % 0.00 %

N/A

N/A
NTSI WisdomTree International .. 0.00 % 0.00 %

+0.34 (+0.68%)

USD 0.32B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.67% 82% B 92% A
Dividend Return 0.64% 20% F 15% F
Total Return 31.31% 82% B 91% A-
Trailing 12 Months  
Capital Gain 42.02% 84% B 91% A-
Dividend Return 0.70% 20% F 8% B-
Total Return 42.72% 84% B 90% A-
Trailing 5 Years  
Capital Gain 413.70% 100% F 98% N/A
Dividend Return 14.32% 20% F 53% F
Total Return 428.02% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.97% 87% B+ 93% A
Dividend Return 42.73% 87% B+ 93% A
Total Return 1.76% 20% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 25.83% 84% B 41% F
Risk Adjusted Return 165.44% 100% F 100% F
Market Capitalization 81.07B 100% F 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 9% 14%
Price/Book Ratio 36.26 4% 3%
Price / Cash Flow Ratio 5.55 4% 57%
Price/Free Cash Flow Ratio 30.60 4% 9%
Management Effectiveness  
Return on Equity 88.57% 100% 99%
Return on Invested Capital 70.15% 96% 99%
Return on Assets 22.80% 100% 100%
Debt to Equity Ratio 14.99% 20% 83%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.